Screener
Rhythm Pharmaceuticals, Inc. RYTM Single reportable segment — Labor and Related Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LaborAndRelatedExpense.
The source filing: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-030549
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| License revenue | - | (5,014) |
| Total revenue, net | 60,112 | 32,704 |
| Cost of sales | 7,157 | 3,648 |
| Global headcount expense | 58,653 | 34,868 |
| Preclinical, clinical and development expense | 18,511 | 19,960 |
| Commercial & medical affairs | 20,264 | 13,249 |
| Corporate, general & administrative | 7,888 | 7,983 |
| Other income (expense), net | (1,704) | (644) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Rhythm Pharmaceuticals, Inc.'s single reportable segment — labor and related expense?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported single reportable segment — labor and related expense of $58.65M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s single reportable segment — labor and related expense changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s single reportable segment — labor and related expense increased by 68.2% year-over-year, from $34.87M to $58.65M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s single reportable segment — labor and related expense?
- Over 3 years (2022 to 2025), Rhythm Pharmaceuticals, Inc.'s single reportable segment — labor and related expense has grown at a 34.6% compound annual growth rate (CAGR), from $70.78M to $172.65M.
- What does single reportable segment — labor and related expense mean?
- This metric tracks the total compensation, benefits, and payroll-related costs for the workforce dedicated to the company's primary business operations. It reflects the human capital investment required to support ongoing research, development, and commercialization activities. High levels of this expense are typical for biopharmaceutical companies heavily reliant on specialized scientific and professional talent.
Ask your AI about Rhythm Pharmaceuticals, Inc.'s single reportable segment — labor and related expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude